Ruben Mesa, Md: Momelotinib Non-Inferior To Ruxolitinib In Myelofibrosis

Ruben Mesa, MD: Momelotinib Non-Inferior to Ruxolitinib in Myelofibrosis

American Society of Hematology

Ruben A. Mesa, MD: Treating Myelofibrosis After Ruxolitinib “Failure”

American Society of Hematology

Momelotinib for the treatment of myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

Momelotinib: a promising drug for patients with myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

Origins and treatment options for anemia in myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

Is momelotinib effective at improving anaemia and splenomegaly in MF?

VJHemOnc – Video Journal of Hematology & HemOnc

Updates on the use of momelotinib for the treatment of MF & clinical trials evaluating this agent

VJHemOnc – Video Journal of Hematology & HemOnc

Momelotinib (Ojjaara) for Myelofibrosis: Top 10 Patients & Physicians should know post FDA Approval

Ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

Momelotinib vs Ruxolitinib in JAKi-naive Patients With Myelofibrosis

Cancer Therapy Advisor

Ruben Mesa, MD on Myelofibrosis (Full Interview)

Rare Disease Report

Dr. Mesa on Ruxolitinib in Myelofibrosis

Targeted Oncology

Ruben Mesa, MD: Ruxolitinib as a Myelofibrosis Treatment

To JAKi or not to JAKi - treating early MF

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Ruben Mesa Discusses the COMFORT Ruxolitinib Trials

Ruxolitinib for myelofibrosis: combinations and dosing strategy

VJHemOnc – Video Journal of Hematology & HemOnc

Mesa Advises Community Oncologists on JAK Inhibitors for Intermediate-Risk Myelofibrosis

Targeted Oncology

Ruben Mesa, MD: Myelofibrosis Patients Frequently Present Symptoms

Pacritinib – is it safe for treating MF?

VJHemOnc – Video Journal of Hematology & HemOnc

Future therapies for MF: pacritinib, momelotinib, fedratinib & other pathways

VJHemOnc – Video Journal of Hematology & HemOnc